Skip to main content

Research Repository

Advanced Search

Discovery of the First‐in‐Class Inhibitors of Hypoxia Up‐Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation

Papadopoulou, Dimitra; Mavrikaki, Vasiliki; Charalampous, Filippos; Tzaferis, Christos; Samiotaki, Martina; Papavasileiou, Konstantinos D.; Afantitis, Antreas; Karagianni, Niki; Denis, Maria C.; Sanchez, Julie; Lane, Robert; Brotzakis, Zacharias Faidon; Skretas, Georgios; Georgiadis, Dimitris; Matralis, Alexios N.; Kollias, George; Papavasileiou, Konstantinos D; Denis, Maria C; Matralis, Alexios N

Discovery of the First‐in‐Class Inhibitors of Hypoxia Up‐Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation Thumbnail


Authors

Dimitra Papadopoulou

Vasiliki Mavrikaki

Filippos Charalampous

Christos Tzaferis

Martina Samiotaki

Konstantinos D. Papavasileiou

Antreas Afantitis

Niki Karagianni

Maria C. Denis

Dr JULIE SANCHEZ JULIE.SANCHEZ@NOTTINGHAM.AC.UK
Nottingham Research and Anne McLarenFellowships (School of Pharmacy)

Zacharias Faidon Brotzakis

Georgios Skretas

Dimitris Georgiadis

Alexios N. Matralis

George Kollias

Konstantinos D Papavasileiou

Maria C Denis

Alexios N Matralis



Abstract

Fibroblasts are key regulators of inflammation, fibrosis, and cancer. Targeting their activation in these complex diseases has emerged as a novel strategy to restore tissue homeostasis. Here, we present a multidisciplinary lead discovery approach to identify and optimize small molecule inhibitors of pathogenic fibroblast activation. The study encompasses medicinal chemistry, molecular phenotyping assays, chemoproteomics, bulk RNA-sequencing analysis, target validation experiments, and chemical absorption, distribution, metabolism, excretion and toxicity (ADMET)/pharmacokinetic (PK)/in vivo evaluation. The parallel synthesis employed for the production of the new benzamide derivatives enabled us to a) pinpoint key structural elements of the scaffold that provide potent fibroblast-deactivating effects in cells, b) discriminate atoms or groups that favor or disfavor a desirable ADMET profile, and c) identify metabolic “hot spots”. Furthermore, we report the discovery of the first-in-class inhibitor leads for hypoxia up-regulated protein 1 (HYOU1), a member of the heat shock protein 70 (HSP70) family often associated with cellular stress responses, particularly under hypoxic conditions. Targeting HYOU1 may therefore represent a potentially novel strategy to modulate fibroblast activation and treat chronic inflammatory and fibrotic disorders.

Citation

Papadopoulou, D., Mavrikaki, V., Charalampous, F., Tzaferis, C., Samiotaki, M., Papavasileiou, K. D., Afantitis, A., Karagianni, N., Denis, M. C., Sanchez, J., Lane, R., Brotzakis, Z. F., Skretas, G., Georgiadis, D., Matralis, A. N., Kollias, G., Papavasileiou, K. D., Denis, M. C., & Matralis, A. N. (2024). Discovery of the First‐in‐Class Inhibitors of Hypoxia Up‐Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation. Angewandte Chemie International Edition, 63(14), Article e202319157. https://doi.org/10.1002/anie.202319157

Journal Article Type Article
Acceptance Date Feb 9, 2024
Online Publication Date Feb 10, 2024
Publication Date Apr 2, 2024
Deposit Date Mar 7, 2025
Publicly Available Date Mar 13, 2025
Journal Angewandte Chemie International Edition
Print ISSN 1433-7851
Electronic ISSN 1521-3773
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 63
Issue 14
Article Number e202319157
DOI https://doi.org/10.1002/anie.202319157
Keywords Activated Fibroblasts, Hypoxia Up-regulated Protein 1, Inflammation, Medicinal Chemistry, Small Molecules
Public URL https://nottingham-repository.worktribe.com/output/31880174
Publisher URL https://onlinelibrary.wiley.com/doi/10.1002/anie.202319157

Files





You might also like



Downloadable Citations